Abstract Library

#4608 A complex and rare association of neuroendocrine and endocrine neoplasms: A case report

Introduction: Neuroendocrine tumours (NETs) are sporadic or genetically inherited heterogenous neoplasms affecting multiple sites.

Conference:

Presenting Author: Cerroni L

Authors: Cerroni L, Filice A, Feola T, Sesti F, Vincenzi L,

Keywords: cushing disease, atypical carcinoid, ileal net, genetics,

#4577 Diagnosis of a cervical carotid paraganglioma: A case report and review of diagnostic imaging approaches

Introduction: Cervical paragangliomas are rare, often non-secreting tumours of neuroectodermal origin. Their diagnosis can be challenging due to the variability of clinical presentations and the diagnostic tests required.

Conference:

Presenting Author: Otmane R

Authors: Otmane R, Boudersa A, Kouadri N,

Keywords: Paraganglioma, cervical, octreoscan,

#4364 Single agent axitinib in the management of patients with progressive pheochromocytoma and paraganglioma

Introduction: Radiolabelled therapy with meta-iodobenzguanine (MIBG) and chemotherapy with a combination of cyclophosphamide, vincristine, and dacarbazine can help manage patients with metastatic pheochromocytoma and paraganglioma (mPPGL). The phase II FIRSTMAPPP study supports the use of the tyrosine kinase inhibitor sunitinib in these malignancies, with median progression-free survival values of 8.9 versus 3.6 months and overall response rates of 31% versus 8% for sunitinib versus placebo. The median duration of sunitinib therapy was 11 months. Concurrent with this study, we launched a single-arm trial to examine the activity of a similar tyrosine kinase inhibitor, axitinib.

Conference:

Presenting Author: Del Rivero J

Authors: Del Rivero J, Fojo T, Edgerly M, Pacak K, Figg W,

Keywords: PPGL, pheochromocytoma, paraganglioma, axitinib, TKI, tyrosinase kinase inhibitors,

#4335 Late nephrotoxicity of peptide receptor radionuclide therapy (PRRT) and impact of selected factors – A single centre cohort study

Introduction: The most common side effect of radioligand therapy is renal damage, early or late. However, limited data exist for the long-term side effects and impact of additional risk factors on renal function in patients treated with PRRT.

Conference:

Presenting Author: Sygula A

Authors: Sygula A, Kropinska A, Kotecka-Blicharz A, Gawlik T, Wycislik M,

Keywords: Neuroendocrine tumour, PRRT, nephrotoxicity, yttrium-90, lutetium-177,

#3842 Long response to 177-Lu DOTATATE of a long malignant metastatic pheochromocytoma survivor

Introduction: A 64-year-old man was admitted on November 2010 with a CT-scan showing a 9cm right adrenal mass and high 24-hour urine metanephrins and cathecolamins. The mass was resected in December 2010 confirming a pT3N1 pheochromocytoma (PHEO). In May 2013 he presented a local recurrence that was resected proving metastatic lymphatic tissue. On May 2014 biochemical progression preceded a CT scan showing retroperitoneal lymphadenophaties with MIBG uptake. He was then treated with 131I-MIBG (two cycles) until May 2015, having biochemical and radiological response. After lymphatic tumor progression in January 2018, he received two more cycles of 131I-MIBG therapy (cumulative dose 800mCi) with proven refractory disease. He continued follow-up until two new abdominal masses appeared in October 2020. A high uptake in the 99Tc octreotide scintigraphy showed somatostatin receptors expression. The patient refused to participate in a clinical trial, so he was treated off-label with 177Lu-DOTATATE (800mCi) four doses from February to July 2021 achieving a near-complete response.

Conference:

Presenting Author: Martin Fernandez de Soignie A

Authors: Martin Fernandez de Soignie A, Martinez Moreno E, Antón-Pascual B, Pantin Gonzalez C, Sanchez Baños N,

Keywords: pheochromocytoma, 177-Lutetium,